Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 2
2017 1
2018 5
2019 9
2020 16
2021 20
2022 15
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux C, Breillat P, Carlier N, Gauzit R, Morbieu C, Pène F, Marin N, Roche N, Szwebel TA, Merkling SH, Treluyer JM, Veyer D, Mouthon L, Blanc C, Tharaux PL, Rozenberg F, Fischer A, Duffy D, Rieux-Laucat F, Kernéis S, Terrier B. Hadjadj J, et al. Among authors: veyer d. Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13. Science. 2020. PMID: 32661059 Free PMC article.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Boland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S; COVID-SER study group; Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. Among authors: veyer d. bioRxiv [Preprint]. 2024 Feb 9:2023.11.20.567873. doi: 10.1101/2023.11.20.567873. bioRxiv. 2024. PMID: 38045308 Free PMC article. Updated. Preprint.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, Puech J, Saliba M, Sahraoui R, Fémy F, Morel N, Dufloo J, Sanjuán R, Mouquet H, André E, Hocqueloux L, Simon-Loriere E, Veyer D, Prazuck T, Péré H, Schwartz O. Planas D, et al. Among authors: veyer d. Nat Commun. 2023 Feb 14;14(1):824. doi: 10.1038/s41467-023-36561-6. Nat Commun. 2023. PMID: 36788246 Free PMC article.
Vaccinia virus evasion of regulated cell death.
Veyer DL, Carrara G, Maluquer de Motes C, Smith GL. Veyer DL, et al. Immunol Lett. 2017 Jun;186:68-80. doi: 10.1016/j.imlet.2017.03.015. Epub 2017 Mar 31. Immunol Lett. 2017. PMID: 28366525 Free article. Review.
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, André E, Schwartz O. Planas D, et al. Among authors: veyer d. Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23. Nature. 2022. PMID: 35016199
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: veyer d. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962
More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients.
Joly C, Desjardins D, Porcher R, Péré H, Bruneau T, Zhang Q, Bastard P, Cobat A, Resmini L, Lenoir O, Savale L, Lécuroux C, Verstuyft C, Roque-Afonso AM, Veyer D, Baron G, Resche-Rigon M, Ravaud P, Casanova JL, Le Grand R, Hermine O, Tharaux PL, Mariette X. Joly C, et al. Among authors: veyer d. Front Immunol. 2023 Nov 21;14:1250214. doi: 10.3389/fimmu.2023.1250214. eCollection 2023. Front Immunol. 2023. PMID: 38077399 Free PMC article.
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Henry-Bolland W, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: veyer d. medRxiv [Preprint]. 2023 May 30:2023.05.25.23290512. doi: 10.1101/2023.05.25.23290512. medRxiv. 2023. PMID: 37398037 Free PMC article. Preprint.
Digital Papillary Adenocarcinoma in Nonacral Skin: Clinicopathologic and Genetic Characterization of 5 Cases.
Kervarrec T, Imbeaud S, Veyer D, Pere H, Puech J, Pekár-Lukacs A, Markiewicz D, Coutts M, Tallet A, Collin C, Berthon P, Bravo IG, Seris A, Jouary T, Macagno N, Touzé A, Cribier B, Battistella M, Calonje E. Kervarrec T, et al. Among authors: veyer d. Am J Surg Pathol. 2023 Oct 1;47(10):1077-1084. doi: 10.1097/PAS.0000000000002096. Epub 2023 Jul 31. Am J Surg Pathol. 2023. PMID: 37505796
81 results